Search Results

DiaCarta, Inc. (“DiaCarta”), a pioneer in developing innovative molecular technologies to transform patient care by providing effective precision diagnostics using liquid biopsy in cancer and infectious diseases has established a strategic collaboration with Capstone Health Alliance, one of the largest regional group purchasing organizations (GPO) in the US healthcare sector.

The Annual Meeting of Stockholders of Capstone Therapeutics Corp., a Delaware corporation, was held on Thursday, March 2, 2023, by request of the majority shareholder, for the following purposes.

SkinCure Oncology, the world leader in providing a comprehensive model for the delivery of Image-Guided Superficial Radiation Therapy, the most advanced nonsurgical treatment for common skin cancer, announced its availability in Alaska at an event at Wasilla’s Capstone Dermatology.

Capstone Development Services Company LLC (“Capstone”) announced today that it has received approval from the U.S. Food and Drug Administration (FDA), as well as authorization from the European Commission for doxorubicin hydrocholoride liposomal injection.

Capstone Development Services Company LLC (“Capstone”) announced today that a biosimilar version of human insulin received authorization from the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) and a Notice of Compliance from Health Canada.

We are in an unprecedented time in neurotherapeutics. Medicines that address the causative disease biology underlying central nervous system

Following disappointing results for an antibiotic candidate whose development program is now being suspended, Spero Therapeutics is looking to extend its cash runway while it focuses on other assets in its pipeline.

Following two layoffs in less than three months, Viracta Therapeutics may have around 18 employees left to advance its efforts to bring lead product candidate nana-val to market.